IP Library Granted Patent US 9,895,432
Granted Patent B2
US 9,895,432 · App. 14/312,162 · Granted Feb 20, 2018

Compositions, methods and therapies for administering antigen peptide

Inventors: Kenichiro Hasumi (Tokyo, JP); Mikio Kuraya (Tokyo, JP)
Assignee: Kenichiro Hasumi
A61K39/0208A61K31/7088A61K38/164A61K39/05A61K45/06C07K14/195C07K14/36A61K2039/53A61K2039/55516A61K2039/55588A61K2039/58A61K2039/645A61K2039/70C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,895,432
App. No.
14/312,162
Granted
Feb 20, 2018
Kind
B2
Abstract

The invention relates to compositions, methods and therapies for the treatment of inflammation caused by infection with Propionibacterium acnes . The compositions include a combination of peptide and anti-TNF. The peptide consists of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived the specific amino acid sequence by deletion, substitution, insertion or addition of one or more amino acids. The administration of the peptide and anti-TNF in therapeutically effective amounts to a patient is effective to suppress, by immune response, inflammation caused by infection with Propionibacterium acnes.

Claims (9)

1. A composition to reduce inflammation in a patient with a Propionibacterium acnes infection, comprising:

a peptide consisting of the amino acid sequence of SEQ NO. 1; and

a TNF inhibitor.

2. The composition of claim 1 , wherein the peptide is in a form of a multivalent antigen peptide obtained by binding a plurality of the peptide consisting of the amino acid sequence of SEQ NO. 1 by a linker.

3. A vaccine to reduce inflammation in a patient with a Propionibacterium acnes infection, comprising:

a peptide consisting of the amino acid sequence of SEQ NO. 1; and

a TNF inhibitor.

4. The vaccine of claim 3 , wherein the peptide is in a form of a multivalent antigen peptide obtained by binding a plurality of the peptide consisting of the amino acid sequence of SEQ NO. 1 by a linker.

5. The vaccine of claim 4 , wherein the peptide and the TNF inhibitor are combined in the form of a composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2017
From: HASUMI, KENICHIRO; KURAYA, MIKIO
To: HASUMI, KENICHIRO
Reel/Frame 040952/0470 →
Continuity (3)
Continuation In Part 13380425
Provisional Application 61396574 · May 27, 2010
Related Publication 20150023997A1 · Jan 22, 2015